JP2025501629A5 - - Google Patents

Info

Publication number
JP2025501629A5
JP2025501629A5 JP2024538674A JP2024538674A JP2025501629A5 JP 2025501629 A5 JP2025501629 A5 JP 2025501629A5 JP 2024538674 A JP2024538674 A JP 2024538674A JP 2024538674 A JP2024538674 A JP 2024538674A JP 2025501629 A5 JP2025501629 A5 JP 2025501629A5
Authority
JP
Japan
Prior art keywords
heterocycloalkyl
alkylene
cycloalkyl
heteroaryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501629A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2022/051592 external-priority patent/WO2023115166A1/en
Publication of JP2025501629A publication Critical patent/JP2025501629A/ja
Publication of JP2025501629A5 publication Critical patent/JP2025501629A5/ja
Pending legal-status Critical Current

Links

JP2024538674A 2021-12-24 2022-12-23 化合物 Pending JP2025501629A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021904274A AU2021904274A0 (en) 2021-12-24 Compounds
AU2021904274 2021-12-24
PCT/AU2022/051592 WO2023115166A1 (en) 2021-12-24 2022-12-23 Compounds

Publications (2)

Publication Number Publication Date
JP2025501629A JP2025501629A (ja) 2025-01-22
JP2025501629A5 true JP2025501629A5 (enExample) 2026-01-07

Family

ID=86900852

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024538674A Pending JP2025501629A (ja) 2021-12-24 2022-12-23 化合物
JP2024538682A Pending JP2025501630A (ja) 2021-12-24 2022-12-23 化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024538682A Pending JP2025501630A (ja) 2021-12-24 2022-12-23 化合物

Country Status (6)

Country Link
US (2) US20250101038A1 (enExample)
EP (2) EP4452937A4 (enExample)
JP (2) JP2025501629A (enExample)
CN (2) CN118696029A (enExample)
CA (2) CA3244229A1 (enExample)
WO (2) WO2023115167A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
WO2021226416A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
EP4396162A4 (en) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc ASYMMETRIC ALLYL TRYPTAMINES
IL313455A (en) 2021-12-15 2024-08-01 Delix Therapeutics Inc Phenoxy and benzyloxy modified psychroplastogens and their uses
WO2023129956A2 (en) 2021-12-30 2023-07-06 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs
EP4525860A2 (en) * 2022-05-20 2025-03-26 Caamtech, Inc. Tryptamine derivatives
IL318840A (en) * 2022-08-11 2025-04-01 Gilgamesh Pharmaceuticals Inc Tryptamines and methods of treating mood disorders
KR20250053871A (ko) * 2022-08-31 2025-04-22 사이빈 아이알엘 리미티드 트립타민 화합물, 조성물, 및 사용 방법
WO2025052388A1 (en) * 2023-09-07 2025-03-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Psychedelic compounds, methods of their preparation and uses thereof
WO2025137581A1 (en) * 2023-12-21 2025-06-26 Atai Therapeutics, Inc. Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1928892A (en) * 1991-06-21 1993-01-25 Smithkline Beecham Plc Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists
GB9718833D0 (en) * 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
CA2353962C (en) * 1998-12-11 2009-09-29 Virginia Commonwealth University Selective 5-ht6 receptor ligands
SI1379239T1 (sl) * 2001-03-29 2008-02-29 Lilly Co Eli N-(2-ariletil)benzilamini, uporabljeni kot antagonisti receptorja 5-ht6
AU2003242245A1 (en) * 2002-06-12 2003-12-31 Sumitomo Pharmaceuticals Co., Ltd. Indole, indazole, and benzazole derivative
US7645886B2 (en) * 2002-12-20 2010-01-12 Ciba Specialty Corporation Synthesis of amines and intermediates for the synthesis thereof
US7994196B2 (en) * 2004-02-12 2011-08-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
US7655691B2 (en) * 2004-09-27 2010-02-02 Sard Howard P Indole compounds useful as serotonin selective agents
WO2007046112A1 (en) * 2005-10-19 2007-04-26 Suven Life Sciences Inc. Arylthioether tryptamine derivatives as functional 5-ht6 ligands
WO2008046155A1 (en) * 2006-10-20 2008-04-24 Dia-B Tech Limited Methods for regulating glucose homeostasis and agents therefor
AU2009214724A1 (en) * 2008-02-11 2009-08-20 Organix Inc. Indole compounds and methods of use thereof
TW201018695A (en) * 2008-07-30 2010-05-16 Ferrer Int 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds
US8349898B2 (en) * 2008-11-18 2013-01-08 Wisconsin Alumni Research Foundation Sigma-1 receptor ligands and methods of use
EP2464227A4 (en) * 2009-08-10 2013-02-20 Galenea Corp COMPOUNDS AND METHODS OF USE
CN102219725B (zh) * 2010-04-16 2013-10-09 中国科学院上海药物研究所 苯并杂环类化合物及其制备方法和用途
AU2012212323A1 (en) * 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
KR20260008838A (ko) * 2020-02-18 2026-01-16 길가메쉬 파마슈티컬스, 인코포레이티드 기분 장애 치료에 사용되기 위한 특이적 트립타민
US20230140635A1 (en) * 2020-03-12 2023-05-04 Bright Minds Biosciences Inc. 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators
WO2021234608A1 (en) * 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CN115867532A (zh) * 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1的抑制剂及其用途
JP2024520485A (ja) * 2021-05-26 2024-05-24 ブライト マインズ バイオサイエンスィズ インコーポレイテッド 複素環式化合物及びその調製方法

Similar Documents

Publication Publication Date Title
JP2025501629A5 (enExample)
JP2025501630A5 (enExample)
IL295371A (en) Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders
JP2025501141A5 (enExample)
JP2023513679A5 (enExample)
JP7502337B2 (ja) Kras g12cインヒビター及びその使用
JP2023512821A5 (enExample)
JP6839104B2 (ja) ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン
EP0495432B1 (en) Hexa-cyclic compound
CN111171047B (zh) 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物
RU2018115569A (ru) Оксаспиропроизводное, способ его получения и его применения в лекарственных средствах
TWI543974B (zh) 苯基-3-氮雜-雙環[3.1.0]己-3-基-甲酮及其作為藥物之用途
JP2020517711A (ja) 2−アミノ−キノリン誘導体
CA2570197C (en) Nk1 antagonists
JP2024508922A5 (enExample)
JP2011511003A5 (enExample)
CA3244224A1 (en) COMPOUNDS
JP2013542189A (ja) 式(I)のpan−CDK阻害剤の調製のための方法、および該調製における中間体
JP2023534803A5 (enExample)
JP2017536399A5 (enExample)
AU2018342423A1 (en) Griseofulvin compound and pharmaceutical use thereof
AU2010313550A1 (en) Spirolactam derivatives and uses of same
US9416143B2 (en) Griseofulvin derivatives
AU2016338602B2 (en) Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
RU2016144410A (ru) Позитивные аллостерические модуляторы никотинового рецептора ацетилхолина